Skip to main content

Advertisement

Table 1 Patient characteristics and outcomes.

From: Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma

  R-CHOP R-EPOCH
No. 99 51
CD4<100/μL 41% 31%
High aaIPI risk (2-3 factors) 59% 69%
Mean age (years +/- standard deviation) 43.5 (+ 8.3) 42.6 (+8.4)
CR rate
Low risk aaIPI (0-1 factors)
High risk aaIPI (2-3 factors)
76% (60%, 88%)
45% (32%, 58%)
88% (62%, 98%)
60% (42%, 76%)
2 year EFS
Low risk aaIPI (0-1 factors)
High risk IPI (2-3 factors)
57% (36%, 73%)
30% (18%, 43%)
81% (51%, 93%)
59% (41%, 74%)
2 year OS
Low risk aaIPI (0-1 factors)
High risk aaIPI (2-3 factors)
66% (43%, 82%)
36% (23%, 50%)
87% (57%, 97%)
62%, (44%, 76%)